MedTrace Logo

D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents

NCT01157429 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to show whether D-cycloserine in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo to reduce symptoms of posttraumatic stress disorder (PTSD) in 13-18 year-old children.

Conditions

Interventions

DRUG

D-cycloserine

D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.

DRUG

Placebo pill

Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.

BEHAVIORAL

CBT

12-session CBT protocol, called Youth PTSD Treatment.

Sponsors & Collaborators

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Tulane University School of Medicine

    lead OTHER

Principal Investigators

  • Michael S Scheeringa, MD, MPH · Tulane University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01157429 on ClinicalTrials.gov